Allworth Financial LP Cuts Stock Position in Repligen Co. (NASDAQ:RGEN)

Allworth Financial LP cut its holdings in Repligen Co. (NASDAQ:RGEN) by 48.0% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 143 shares of the biotechnology company’s stock after selling 132 shares during the quarter. Allworth Financial LP’s holdings in Repligen were worth $26,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Fortis Capital Advisors LLC boosted its stake in Repligen by 32.7% during the first quarter. Fortis Capital Advisors LLC now owns 272 shares of the biotechnology company’s stock worth $46,000 after buying an additional 67 shares during the period. Signaturefd LLC boosted its stake in Repligen by 44.1% during the third quarter. Signaturefd LLC now owns 281 shares of the biotechnology company’s stock worth $45,000 after buying an additional 86 shares during the period. First Horizon Advisors Inc. boosted its stake in Repligen by 14.8% during the third quarter. First Horizon Advisors Inc. now owns 675 shares of the biotechnology company’s stock worth $107,000 after buying an additional 87 shares during the period. Daiwa Securities Group Inc. boosted its stake in Repligen by 3.2% during the third quarter. Daiwa Securities Group Inc. now owns 3,200 shares of the biotechnology company’s stock worth $509,000 after buying an additional 100 shares during the period. Finally, State of Michigan Retirement System boosted its stake in Repligen by 0.8% during the fourth quarter. State of Michigan Retirement System now owns 12,453 shares of the biotechnology company’s stock worth $2,239,000 after buying an additional 100 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Repligen

In related news, CEO Anthony Hunt sold 16,707 shares of Repligen stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $197.44, for a total value of $3,298,630.08. Following the completion of the sale, the chief executive officer now directly owns 185,249 shares in the company, valued at $36,575,562.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Repligen news, Director Karen A. Dawes sold 1,000 shares of Repligen stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $193.35, for a total value of $193,350.00. Following the transaction, the director now owns 87,367 shares in the company, valued at $16,892,409.45. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Anthony Hunt sold 16,707 shares of Repligen stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $197.44, for a total value of $3,298,630.08. Following the completion of the transaction, the chief executive officer now owns 185,249 shares in the company, valued at approximately $36,575,562.56. The disclosure for this sale can be found here. Insiders sold 25,597 shares of company stock worth $5,039,532 over the last three months. 1.10% of the stock is owned by corporate insiders.

Repligen Stock Performance

RGEN stock opened at $171.53 on Monday. The company has a debt-to-equity ratio of 0.26, a current ratio of 7.02 and a quick ratio of 5.75. The business has a 50-day moving average price of $192.16 and a 200 day moving average price of $173.21. The company has a market capitalization of $9.58 billion, a P/E ratio of 238.24, a PEG ratio of 5.62 and a beta of 1.02. Repligen Co. has a 1-year low of $110.45 and a 1-year high of $211.13.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported $0.33 earnings per share for the quarter, meeting the consensus estimate of $0.33. The firm had revenue of $155.74 million during the quarter, compared to the consensus estimate of $155.38 million. Repligen had a return on equity of 5.00% and a net margin of 6.51%. The firm’s quarterly revenue was down 16.6% on a year-over-year basis. During the same period in the previous year, the company posted $0.68 earnings per share. As a group, equities research analysts forecast that Repligen Co. will post 1.46 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have commented on the stock. KeyCorp lifted their price objective on shares of Repligen from $210.00 to $220.00 and gave the stock an “overweight” rating in a research note on Thursday, February 15th. Stifel Nicolaus lifted their price objective on shares of Repligen from $165.00 to $207.00 and gave the stock a “buy” rating in a research note on Thursday, February 22nd. Finally, JPMorgan Chase & Co. lifted their target price on Repligen from $170.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 20th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $196.70.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.